Please login to the form below
Menarini
This page shows the latest Menarini news and features for those working in and with pharma, biotech and healthcare.
New cancer meds and drug extensions top CHMP recommendations
This includes Adenuric, blockbuster oncology treatment Avastin (bevacizumab) from Roche; AbbVie's auto-inflammatory drug Humira (adalimumab), Menarini's gout drug Adenuric, (febuxostat), the rare disease drug for kidney disease Soliris
Latest news
-
Campaigns recognised at German health comms awards
Among the winners was Schmittgall, which picked up two awards, including the disease awareness prize for its TheraKey project for Berlin Chemie, a subsidiary of Italy's Menarini.
-
Menarini launches urology campaign in Greece
PE information push includes Not Just A Moment website. Menarini is supporting a new awareness initiative to educate men about premature ejaculation.
-
Developing your patient-centric strategy
AbbVie. 4. Menarini. 5. Janssen. Source: PatientView. Nevertheless, it's worth revisiting the announcement of ViiV's birth four and a half years ago.
-
Five companies breach ABPI code
Lundbeck, A Menarini Pharma, Bayer, HRA Pharma UK and GlaxoSmithKline named by PMCPA. ... Lundbeck, A Menarini Pharma, Bayer, HRA Pharma UK and GlaxoSmithKline (GSK) were named by the PMCPA – the Code's administrator - in medical, pharmaceutical and
-
Developing therapeutic cancer vaccines
Another anti-idiotypic vaccine is Menarini's abagovomab, which mimics an epitope on the tumour-associated antigen, CA125.
More from news
Approximately 4 fully matching, plus 22 partially matching documents found.
Latest Intelligence
-
Pharma deals in April 2015
Dr Reddy's, Menarini and Cipher Pharmaceuticals have acquired or licensed rights to products in South Asia, Asia Pacific (ex-Japan) and North America and Mexico, respectively. . ... Menarini AP will be responsible for the clinical development,
-
Medius Deal Watch table for April 2015
120. 4SC AG/Menarini. Licensing and development agreement. Resminostat (oral HDAC) for hepatocellular carcinoma.
-
Deal Watch table for July 2013
130‡. Vivus / Berlin-Chemie (Menarini). Licence, commercialisation, supply. Spedra (avanafil) for erectile dysfunction (approved).
-
Pharma investment in Indonesia
Two years prior to its acquisition by the Italian Menarini group in Dec 2012, the Invida Group acquired 70 per cent stake of Indonesian pharmaceutical manufacturer MUGI.
-
Pharma deals during October 2012
indications. Whilst Oxford BioTherapeutics will be responsible for the discovery activities, Menarini will lead on the manufacture and clinical development of each programme. ... Asia and Latin America. Whilst no financial terms have been disclosed, a
More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.
Latest from PMHub
-
Frontera Group
Medskin Solutions . Menarini Farmaceutica Internazionale . Merck. Merz Pharmaceuticals. Mitsubishi Pharma Europe.
-
Life wins at the Rx Club Show
Menarini. Life also picked up 6 awards of excellence in the print category for Life self-promotion and for clients Galderma and Abbott. .
-
SEVEN STONES
Alimera. Bayer. BD. Celgene. Dr Falk. GE. Jazz. Menarini. MSD. Myzone.
More from PMHub
Approximately 1 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Medical Editor
-
Competitive
-
Healthcare Account Director
-
Competitive
-
Healthcare Lead Copywriter
-
Competitive
-
Healthcare Senior Account Manager
-
Competitive
- Sales Director, Healthcare communications agency, London/ SE UK
-
Six figure salary
- Account Manager Healthcare / Pharmaceutical Sector
-
Negotiable Salary
- GSK’s PD-1 inhibitor dostarlimab shows updated promise in dMMR solid tumours
- Moderna cooperating with investigation into possible COVID-19 vaccine allergic reactions
- Valneva set to begin commercial manufacturing of COVID-19 vaccine within days
- Sinovac’s COVID-19 vaccine appears safe in older adults
- Pfizer introduces new logo in a ‘shift from commerce to science’
- New study identifies drugs that are safe to use in COVID-19 treatment
- Mistrust in medical research: a patient perspective
- Real-world evidence: breaking boundaries in rare disease
- Live Webinar: Importance of Highlighting Patient Voices, Workforce Well-Being, and Health Literacy During and After the Pandemic
- The heavy toll of COVID-19 on cancer patients
- Unpacking rare diseases in the first edition of Delta magazine
- Virtual HealthTech conference powered by Impetus Digital: A Customer Story
PMHub
KVA Digital
KVA is an award winning full-service digital communications & brand experience agency. Our healthcare expertise blends creative ‘outside-the-box’ thinking with...
Latest intelligence
- Mistrust in medical research: a patient perspective
- The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
- Real-world evidence: breaking boundaries in rare disease
- Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
- The heavy toll of COVID-19 on cancer patients
- We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...
Quick links
Infographics
